Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

MN Gandy, M McIldowie, K Lewis, AM Wasik, D Salomonczyk, K Wagg, ZA Millar, D Tindiglia, P Huot, T Johnston, S Thiele, B Nguyen, Nicholas Barnes, JM Brotchie, MT Martin-Iverson, J Nash, John Gordon, MJ Piggott

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel alpha-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.
Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalMedchemcomm
Volume1
Issue number4
Early online date7 Sep 2010
DOIs
Publication statusPublished - 1 Oct 2010

Fingerprint

Dive into the research topics of 'Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity'. Together they form a unique fingerprint.

Cite this